CA4P Is Well Tolerated, May Benefit Platinum-resistant Ovarian Cancer Patients, Trial Shows
News
Data from the second interim analysis of the ongoing Phase 2/3 FOCUS study has shown that Mateon Therapeutics’ CA4P (combretastatin a4-phosphate), also known as fosbretabulin, may prolong the time to disease ... Read more